Manufacturing Sites (Cardiovascular and Neuromodulation Products)
FY, 2023
Manufacturing Sites (Nutritional Products)
FY, 2023
Manufacturing Sites (Established Pharmaceutical Products)
FY, 2023
Metrics | FY, 2021 | FY, 2022 | FY, 2023 |
---|---|---|---|
Manufacturing Sites (Cardiovascular and Neuromodulation Products) | 27 | 28 | 31 |
Manufacturing Sites (Nutritional Products) | 14 | 14 | 14 |
Manufacturing Sites (Established Pharmaceutical Products) | 25 | 24 | 24 |
Manufacturing Sites (Diagnostic Products) | 24 | 22 | 21 |
Facility Space, sq. ft. | 43M | 43M | 44M |
Remaining Performance Obligations (Medical Devices) | $435.0M | $432.0M | $478.0M |
Remaining Performance Obligations (Diagnostic Products) | $4.0B | $4.0B | $4.4B |
Reportable Segments | 4 | 4 | 4 |
Community
Employees
Environment
Governance
Source:CSRHub